|
1
|
Ding W, Knox TR, Tschumper RC, Wu W,
Schwager SM, Boysen JC, Jelinek DF and Kay NE: Platelet-derived
growth factor (PDGF)-PDGF receptor interaction activates bone
marrow-derived mesenchymal stromal cells derived from chronic
lymphocytic leukemia: implications for an angiogenic switch. Blood.
116:2984–2993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li W, Zhou Y, Yang J, Zhang X, Zhang H,
Zhang T, Zhao S, Zheng P, Huo J and Wu H: Gastric cancer-derived
mesenchymal stem cells prompt gastric cancer progression through
secretion of interleukin-8. J Exp Clin Cancer Res. 34:522015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arai F, Hirao A, Ohmura M, Sato H,
Matsuoka S, Takubo K, Ito K, Koh GY and Suda T: Tie2/angiopoietin-1
signaling regulates hematopoietic stem cell quiescence in the bone
marrow niche. Cell. 118:149–161. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang F, Wang M, Yang T, Cai J, Zhang Q,
Sun Z, Wu X, Zhang X, Zhu W, Qian H, et al: Gastric cancer-derived
MSC-secreted PDGF-DD promotes gastric cancer progression. J Cancer
Res Clin Oncol. 140:1835–1848. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vianello F, Villanova F, Tisato V, Lymperi
S, Ho KK, Gomes AR, Marin D, Bonnet D, Apperley J, Lam EW, et al:
Bone marrow mesenchymal stromal cells non-selectively protect
chronic myeloid leukemia cells from imatinib-induced apoptosis via
the CXCR4/CXCL12 axis. Haematologica. 95:1081–1089. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sison EA and Brown P: The bone marrow
microenvironment and leukemia: Biology and therapeutic targeting.
Expert Rev Hematol. 4:271–283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Hayre M, Salanga CL, Kipps TJ, Messmer
D, Dorrestein PC and Handel TM: Elucidating the CXCL12/CXCR4
signaling network in chronic lymphocytic leukemia through
phosphopro-teomics analysis. PLoS One. 5:e117162010. View Article : Google Scholar
|
|
8
|
Li X, Guo H, Duan H, Yang Y, Meng J, Liu
J, Wang C and Xu H: Improving chemotherapeutic efficiency in acute
myeloid leukemia treatments by chemically synthesized peptide
interfering with CXCR4/CXCL12 axis. Sci Rep. 5:162282015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han TT, Fan L, Li JY and Xu W: Role of
chemokines and their receptors in chronic lymphocytic leukemia:
Function in microenvironment and targeted therapy. Cancer Biol
Ther. 15:3–9. 2014. View Article : Google Scholar :
|
|
10
|
Möhle R, Failenschmid C, Bautz F and Kanz
L: Overexpression of the chemokine receptor CXCR4 in B cell chronic
lymphocytic leukemia is associated with increased functional
response to stromal cell-derived factor-1 (SDF-1). Leukemia.
13:1954–1959. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Lourdes Perim A, Amarante MK,
Guembarovski RL, de Oliveira CE and Watanabe MA: CXCL12/CXCR4 axis
in the pathogenesis of acute lymphoblastic leukemia (ALL): A
possible therapeutic target. Cell Mol Life Sci. 72:1715–1723. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alsayed Y, Ngo H, Runnels J, Leleu X,
Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM,
Jia X, et al: Mechanisms of regulation of CXCR4/SDF-1
(CXCL12)-dependent migration and homing in multiple myeloma. Blood.
109:2708–2717. 2007.
|
|
13
|
Nervi B, Ramirez P, Rettig MP, Uy GL, Holt
MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, et
al: Chemo-sensitization of acute myeloid leukemia (AML) following
mobilization by the CXCR4 antagonist AMD3100. Blood. 113:6206–6214.
2009. View Article : Google Scholar :
|
|
14
|
Sison EA, Magoon D, Li L, Annesley CE, Rau
RE, Small D and Brown P: Plerixafor as a chemosensitizing agent in
pediatric acute lymphoblastic leukemia: efficacy and potential
mechanisms of resistance to CXCR4 inhibition. Oncotarget.
5:8947–8958. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shen ZH, Zeng DF, Ma YY, Zhang X, Zhang C
and Kong PY: Are there any new insights for G-CSF and/or AMD3100 in
chemotherapy of haematological malignants? Med Oncol. 32:2622015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kashyap MK, Kumar D, Jones H,
Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR,
Sabbatini P, Cohen LJ, et al: Ulocuplumab (BMS-936564/MDX1338): A
fully human anti-CXCR4 antibody induces cell death in chronic
lymphocytic leukemia mediated through a reactive oxygen species-
dependent pathway. Oncotarget. 7:2809–2822. 2016.
|
|
17
|
Niedermeier M, Hennessy BT, Knight ZA,
Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM and
Burger JA: Isoform-selective phosphoinositide 3′-kinase inhibitors
inhibit CXCR4 signaling and overcome stromal cell-mediated drug
resistance in chronic lymphocytic leukemia: A novel therapeutic
approach. Blood. 113:5549–5557. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu CC, Wang H, Wang WD, Zhu MY, Geng QR
and Lu Y: Consolidation therapy of arsenic trioxide alternated with
chemotherapy achieves remarkable efficacy in newly diagnosed acute
promyelocytic leukemia. Onco Targets Ther. 8:3297–3303.
2015.PubMed/NCBI
|
|
19
|
Soignet SL, Frankel SR, Douer D, Tallman
MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA,
Steinherz P, et al: United States multicenter study of arsenic
trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol.
19:3852–3860. 2001.PubMed/NCBI
|
|
20
|
Shen Y, Shen ZX, Yan H, Chen J, Zeng XY,
Li JM, Li XS, Wu W, Xiong SM, Zhao WL, et al: Studies on the
clinical efficacy and pharmacokinetics of low-dose arsenic trioxide
in the treatment of relapsed acute promyelocytic leukemia: A
comparison with conventional dosage. Leukemia. 15:735–741. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chendamarai E, Ganesan S, Alex AA, Kamath
V, Nair SC, Nellickal AJ, Janet NB, Srivastava V, Lakshmi KM,
Viswabandya A, et al: Comparison of newly diagnosed and relapsed
patients with acute promyelocytic leukemia treated with arsenic
trioxide: Insight into mechanisms of resistance. PLoS One.
10:e01219122015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lengfelder E, Lo-Coco F, Ades L,
Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia
M, Huerta AJ, et al European LeukemiaNet: Arsenic trioxide-based
therapy of relapsed acute promyelocytic leukemia: Registry results
from the European Leukemia Net. Leukemia. 29:1084–1091. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salmon JM, Bots M, Vidacs E, Stanley KL,
Atadja P, Zuber J and Johnstone RW: Combining the differentiating
effect of panobinostat with the apoptotic effect of arsenic
trioxide leads to significant survival benefit in a model of
t(8;21) acute myeloid leukemia. Clin Epigenetics. 7:22015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oancea C, Rüster B, Brill B, Roos J,
Heinssmann M, Bug G, Mian AA, Guillen NA, Kornblau SM, Henschler R,
et al: STAT activation status differentiates leukemogenic from
non-leukemogenic stem cells in AML and is suppressed by arsenic in
t(6;9)-positive AML. Genes Cancer. 5:378–392. 2014.
|
|
25
|
Evens AM, Tallman MS and Gartenhaus RB:
The potential of arsenic trioxide in the treatment of malignant
disease: Past, present, and future. Leuk Res. 28:891–900. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J,
Cai X, Han ZG, Ni JH, Shi GY, Jia PM, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute
promyelocytic leukemia (APL): I. As2O3 exerts
dose-dependent dual effects on APL cells. Blood. 89:3345–3353.
1997.PubMed/NCBI
|
|
27
|
Lallemand-Breitenbach V, Zhu J, Chen Z and
de Thé H: Curing APL through PML/RARA degradation by
As2O3. Trends Mol Med. 18:36–42. 2012.
View Article : Google Scholar
|
|
28
|
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou
L, Huang Y, Zhang JW, Xiong SM, Chen SJ, et al: Arsenic
trioxide-induced apoptosis and differentiation are associated
respectively with mitochondrial transmembrane potential collapse
and retinoic acid signaling pathways in acute promyelocytic
leukemia. Leukemia. 14:262–270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guan L, Han B, Li Z, Hua F, Huang F, Wei
W, Yang Y and Xu C: Sodium selenite induces apoptosis by
ROS-mediated endoplasmic reticulum stress and mitochondrial
dysfunction in human acute promyelocytic leukemia NB4 cells.
Apoptosis. 14:218–225. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Menheniott TR, Judd LM and Giraud AS:
RUNX3 methylation and anti-tumor immunity. Oncoscience. 2:789–790.
2015.PubMed/NCBI
|
|
31
|
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada
K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al: RUNX3, a
novel tumor suppressor, is frequently inactivated in gastric cancer
by protein mislocalization. Cancer Res. 65:7743–7750.
2005.PubMed/NCBI
|
|
32
|
Yano T, Ito K, Fukamachi H, Chi XZ, Wee
HJ, Inoue K, Ida H, Bouillet P, Strasser A, Bae SC, et al: The
RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells
undergoing transforming growth factor beta-induced apoptosis. Mol
Cell Biol. 26:4474–4488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chi XZ, Yang JO, Lee KY, Ito K, Sakakura
C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, et al: RUNX3 suppresses
gastric epithelial cell growth by inducing p21(WAF1/Cip1)
expression in cooperation with transforming growth factor
{beta}-activated SMAD. Mol Cell Biol. 25:8097–8107. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ito K, Lim AC, Salto-Tellez M, Motoda L,
Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, et al: RUNX3
attenuates β-catenin/T cell factors in intestinal tumorigenesis.
Cancer Cell. 14:226–237. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pande S, Ali SA, Dowdy C, Zaidi SK, Ito K,
Ito Y, Montecino MA, Lian JB, Stein JL, van Wijnen AJ, et al:
Subnuclear targeting of the Runx3 tumor suppressor and its
epigenetic association with mitotic chromosomes. J Cell Physiol.
218:473–479. 2009. View Article : Google Scholar
|
|
36
|
Okorokov AL, Rubbi CP, Metcalfe S and
Milner J: The interaction of p53 with the nuclear matrix is
mediated by F-actin and modulated by DNA damage. Oncogene.
21:356–367. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bae SC, Takahashi E, Zhang YW, Ogawa E,
Shigesada K, Namba Y, Satake M and Ito Y: Cloning, mapping and
expression of PEBP2 alpha C, a third gene encoding the mammalian
Runt domain. Gene. 159:245–248. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Beekman AM and Howell LA: Small-molecule
and peptide inhibitors of the pro-survival protein Mcl-1. Chem Med
Chem. 11:802–813. 2016. View Article : Google Scholar
|
|
39
|
Belmar J and Fesik SW: Small molecule
Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther.
145:76–84. 2015. View Article : Google Scholar :
|
|
40
|
Cuconati A, Mukherjee C, Perez D and White
E: DNA damage response and MCL-1 destruction initiate apoptosis in
adenovirus-infected cells. Genes Dev. 17:2922–2932. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bose P and Grant S: Mcl-1 as a Therapeutic
Target in Acute Myelogenous Leukemia (AML). Leuk Res Rep. 2:12–14.
2013.PubMed/NCBI
|
|
42
|
Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim
MY, Oak CY, Chung CY, Park HC, Kim JS, et al: Myeloid cell
leukemia-1 is associated with tumor progression by inhibiting
apoptosis and enhancing angiogenesis in colorectal cancer. Am J
Cancer Res. 5:101–113. 2014.
|
|
43
|
Lee JS, Tang SS, ortiz V, Vo TT and Fruman
DA: MCL-1-independent mechanisms of synergy between dual PI3K/mTOR
and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget.
6:35202–35217. 2015.PubMed/NCBI
|
